Caroline Moore

Caroline Moore MD FRCS(Urol), Reader in Urology, Division of Surgical & Interventional Science, University College London, Honorary Consultant Urological Surgeon, University College London Hospitals Trust.

My joint appointment between the Division of Surgical & Interventional Sciences at UCL, and the Department of Urology at University College London Hospital Trust enables me to concentrate on the development and delivery of clinical trials and clinical practice focussing on the outcomes associated with the use of an image guided prostatę cancer pathway. At UCL/UCLH we have the largest image guided diagnostic, surveillance and focal therapy programme. As well as outcomes data from a range of clinical trials we have a robust registry of men who have undergone focal therapy for prostate cancer, both at our centre (the largest in Europe) and across the UK.

I am committed to the development of robust data systems to collect and collate outcomes data across clinical pathways and within clinical trials, in prostate cancer, working with both national and international collaborators. My work includes leading the True NTH UK Post Surgery follow up project to develop an electronically delivered psychometrically robust patient reported outcome measure to detect change over time in individual men who have had radical prostatectomy. This project is looking to develop appropriate benchmarks for patient reported outcomes in radical prostatectomy in the UK, and includes a Surgical Forum where surgeons can discuss linked operative and outcomes data, with a view to disseminating best practice.

I am also a participant in the Movember Global Action Project 3: Active Surveillance, with a particular interest in the contribution of MR-derived outcomes data to this international dataset.

My current portfolio in prostate cancer diagnosis and management includes MRI-targeted biopsy studies (PICTURE & SmartTarget), a European multi-centre randomised controlled study of active surveillance and focal therapy for localised prostate cancer (PCM 301), and a randomised controlled trial of Magnetic resonance imaging in Primary Prostate cancer after Exposure to Dutasteride (MAPPED). I set up an international working party on Standards in Reporting in mri-Targeted biopsy (START) in October 2012, and am developing an international randomised controlled study of MRI-targeted biopsy vs standard TRUS biopsy with the START consortium (PRECISION).